Comparing clinical outcomes of NOACs with warfarin on atrial fibrillation with Valvular heart diseases: a meta-analysis
Abstract Background Warfarin is the standard of care and NOAC (Novel oral anticoagulants) are a group of newer drugs for such purposes. NOAC has a generally better profile (Clear interaction, less side effect, require less monitoring). However, its efficacy on valvular atrial fibrillation remains un...
Main Authors: | Qiyu He, Chun-Yat Sze, Tin-Yau Shum, Guang Hao, Nga-Yin Belinda Wong, Tat-Hang Sin, Wei Wei, Sujian Xia |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-05-01
|
Series: | BMC Cardiovascular Disorders |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12872-019-1089-0 |
Similar Items
-
Use of Novel oral anticoagulants (NOACs) in patients with risk of stroke in non valvular Atrial Fibrillation (AF)
by: Fawad Farooq, et al.
Published: (2017-12-01) -
Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
by: Faye L. Norby, et al.
Published: (2017-09-01) -
Impact of Reduced-Dose Nonvitamin K Antagonist Oral Anticoagulants on Outcomes Compared to Warfarin in Korean Patients with Atrial Fibrillation: A Nationwide Population-Based Study
by: Sola Han, et al.
Published: (2021-08-01) -
Comparison of the Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Yasmin de Souza Lima Bitar, et al.
Published: (2021-09-01) -
Efficacy and safety of oral anticoagulant therapy in frail patients with atrial fibrillation
by: Giuseppe Patti, et al.
Published: (2018-06-01)